7 results about "Inflammation mediators" patented technology

The invention discloses an application of a Yinxiaonaotong soft capsule in preparation of a medicine for preventing and treating acute lung injury, and experimental research shows that the Yinxiaonaotong soft capsule can significantly improve lung histopathologic injury of an acute lung injury mouse model activated and induced by a complement bypass and relieve inflammatory cell infiltration. The mechanism of action is as follows: the Yindanaotong can effectively inhibit the expression of key inflammatory mediators (TNF-alpha, IL-6) and adhesion molecules (ICAM-1, P-selectin) in lung tissues and serum. Meanwhile, the medicine can down-regulate the mRNA transcriptional level of NF-kappa B p65, JNK, p38 MAPK and STAT3 signal channel related genes in lung tissues and inhibit phosphorylation activation of corresponding proteins. The results comprehensively show that the Yindan Xinnaotong compound intervenes in an inflammation signal channel through multiple targets, and plays roles in resisting inflammation and protecting lung tissues, so that the Yindan Xinnaotong compound can be used for preparing medicines for preventing and / or treating acute lung injury.

The invention discloses application of phenylpropionic acid as a PPAR-gamma agonist in preparation of a product for preventing, relieving and / or treating enteritis, relates to the technical field of medicines, and solves the problems that the existing medicines are poor in curative effect and do not have dual effects of preventing and relieving enteritis at the same time. Phenylpropionic acid is used as a PPAR-gamma agonist, can reduce infiltration of inflammatory cells into intestinal tissues by activating PPAR-gamma receptors and inhibiting expression of adhesion molecules, and can also regulate functions of immune cells, reduce release of inflammatory mediators, remarkably reduce generation of proinflammatory cytokines and effectively relieve intestinal inflammatory response, so that the intestinal inflammatory response is reduced, and the intestinal inflammatory response is reduced. Therefore, immune-mediated intestinal injury is relieved, immune response is adjusted, and the anti-inflammatory effect is remarkable; by inhibiting the expression of a fibrosis promoting factor, the process of intestinal fibrosis is slowed down or reversed, and complications such as intestinal stenosis are prevented.

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.

This invention provides the application of wrinkled papaya polyphenols in the preparation of drugs for treating osteoarthritis. The wrinkled papaya polyphenols are used in the preparation of drugs that reduce the release of pro-inflammatory cytokines and the inflammatory mediator NO in primary chondrocytes, and / or reduce the mRNA expression of inflammation-related enzymes, and / or inhibit the phosphorylation of proteins related to the NF-κB signaling pathway. To test and clarify the anti-inflammatory effect of wrinkled papaya polyphenols, an ADTC5 primary chondrocyte inflammation model was constructed for observation. The results showed that wrinkled papaya polyphenols significantly inhibited IL-1β-induced inflammation in ADTC5 primary chondrocytes, effectively reduced the secretion of pro-inflammatory cytokines (IL-6 and TNF-α), inhibited the release of the inflammatory mediator NO, downregulated the mRNA expression of inflammatory enzymes (iNOS and Cox-2), and reduced the phosphorylation of IκBα and p65 proteins.

The application discloses a composite antibacterial pet external spray containing plant extracts and a preparation method thereof, and belongs to the technical field of pet care products. The external spray contains, in percentage by mass, 0.5-1.0% of cortex dictamni root extract, 0.75-1.5% of lycopersicum fruit extract, 0.75-1.5% of artemisia argyi leaf extract and 5-8% of chrysanthemum parthenium pure distillate, and can be further combined with auxiliary components such as emulsifiers and preservatives. The cortex dictamni root extract is prepared by using a supercritical CO2 extraction method combined with a specific composite entrainer, and active components are fully reserved; the spray is prepared by using a water phase and an oil phase in steps and is formed by high-shear emulsification, and has good stability. The product shows high bacteriostatic effects on staphylococcus aureus, salmonella and candida albicans, can significantly reduce the contents of inflammatory mediators NO and proinflammatory factors IL-1beta, has the effects of bacteriostasis, sterilization and anti-inflammation, is suitable for the preparation of pet skin care related products, and has a wide application prospect.

Methods for characterizing disease activity in patients with systemic lupus erythematosus (SLE). These methods include obtaining blood, serum, plasma, or urine samples from the patient; assessing the expression of biomarkers selected from IFN-α, IL-10, BlyS, IL-7, IFN-γ, TRAIL, IL-15, IP-10 / CXCL10, and IL-4 in the samples; assessing the expression of inflammatory mediators selected from TNFRII, resistin, and osteopontin (OPN) in the samples; assessing SLE-related autoantibody-specific biomarkers selected from dsDNA, chromatin, RiboP, Ro / SSA, La / SSB, Sm, SmRNP, and RNP in the samples; and calculating the Lupus Disease Activity (Immune) Index (LDAII / L-DAI) score. The LDAII / L-DAI score can distinguish between active and low lupus disease activity. Treatment methods are also provided, including administration after determining that the patient has a prognostic risk of transitioning to classified SLE but before reaching the clinical disease classification.

This invention proposes a coordination assembly-modified microorganism, its preparation method, and its application, belonging to the field of biomedical materials technology. This invention obtains catechol lipid-modified microorganisms by reacting catechol lipid molecules with microbial culture via a thin-film hydration method. These microorganisms are then contacted with metal ions to form a catechol lipid-metal-modified microorganism through coordination. Further contact with polyphenolic compounds leads to the coordination assembly of a catechol lipid-metal-polyphenol complex, thus forming the coordination assembly-modified microorganism. This invention employs a novel bacterial surface coordination assembly method and, through the combined regulation of microorganisms and inflammatory mediators, achieves a combined treatment of periodontitis and neuroinflammatory conditions related to depression and cognitive impairment. The modification method of this invention is universal; it can be used to construct engineered bacteria by replacing different bacterial carriers and different metals and polyphenolic compounds.